StockIQ.techNeurocrine Biosciences, Inc. (NBIX) Stock Analysis
Free AI-powered analysis and research for Neurocrine Biosciences, Inc. stock
Sector: Healthcare
NBIX snapshot
Data as of 3 Nov 2026 close. Updated daily.
Neurocrine Biosciences, Inc. scores 100/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 70% of its 52-week range, up 17.5% over the past year. Latest reported figures show a profit margin of 20.9%, return on equity of 22.1% and revenue growth of +39.5%.
What is driving the score
- Mixed Trend: +0
- MACD Bullish: +8
- Strong Revenue Growth (39.5%): +8
- Excellent Profit Margin (20.9%): +10
- Low Debt (0.12 D/E): +8
- Excellent ROE (22.1%): +8
- Strong Long-term Uptrend: +8
- Healthy Momentum (+17.5% over 1 year): +7
- High Volume (1.7x): +3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full NBIX report
Neurocrine Biosciences, Inc. (NBIX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze NBIX Now →📰 Latest Update
NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
Tue, November 3, 2026 at 3:15 PM UTC 2 min read
Neurocrine Biosciences (NBIX) reported a strong third-quarter 2026, with adjusted earnings per share of $3.29, exceeding estimates, and total revenues of $1.12 billion, up 41% year over year. The company raised its full-year sales forecast for Ingrezza to $2.90-$2.925 billion, driven by record prescriptions and contributions from Crenessity and Vykat XR. Following the results, shares rose 6% in after-hours trading, reflecting positive market sentiment.